drugset / Trial / NCT06022146

A Novel Therapy With a 1-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB-YOUTH Study)

NCT06022146

Phase 3 Recruiting 3520 enrolled Huashan Hospital
RandomizedParallel-groupOpen-labelPrevention

Summary

This is a prospective, multi-center, open-label, cluster randomized controlled clinical trial conducted in school settings to estimate the non-inferiority effect of 1H3P3 compared with 3HR.

Timeline

Start
2023-09-01
Primary completion
2026-09-01
Completion
2026-09-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Isoniazid Small molecule 400 mg
Comparator Isoniazid Small molecule
Comparator Rifampin Small molecule
Subject Rifapentine Small molecule 450 mg